Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.66 |
| ▸ | RAB9A | P51151 | 7/20 | 0.66 |
| ▸ | NPC1 | O15118 | 5/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | AR | P10275 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | OGA | O60502 | 3/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24359018 | 0.88 | RAB9A (0.66) | SMN1; SMN2RAB9ANPC1HRH3MAPT | |
| SCHEMBL809829 | 0.80 | RAB9A (1.00) | SMN1; SMN2RAB9ANPC1MAPTGAA | |
| Hydrogen Sulfide SCHEMBL11606123 | 0.78 | RAB9A (0.97) | SMN1; SMN2RAB9ANPC1MAPTGAA | |
| SCHEMBL9963514 | 0.76 | RAB9A (0.74) | SMN1; SMN2RAB9ANPC1MAPTGAA | |
| SCHEMBL12041449 | 0.75 | HRH3 (1.00) | HRH3 | |
| SCHEMBL14810634 | 0.75 | RAB9A (0.64) | SMN1; SMN2RAB9ANPC1MAPTGAA | |
| SCHEMBL21154008 | 0.75 | RAB9A (0.64) | SMN1; SMN2RAB9ANPC1MAPTGAA | |
| SCHEMBL18344064 | 0.75 | SMN1; SMN2 (0.79) | SMN1; SMN2RAB9ANPC1MAPTGAA | |
| SCHEMBL21588444 | 0.74 | RAB9A (0.58) | SMN1; SMN2RAB9ANPC1HRH3MAPT | |
| SCHEMBL16896300 | 0.74 | KCNH2 (0.62) | SMN1; SMN2RAB9ANPC1HRH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127263-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127263-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | SMN1; SMN2 445/4885RAB9A 1905/4885NPC1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.